Last reviewed · How we verify
NCT06860555
Hyperspectral Drusen Classification
trial testing Mydriatic Hyperspectral retinal Camera, (MHRC) and Optical coherence tomography (OCT) in Dry Age Related Macular Degeneration in 112 participants. Completed in 15 August 2023.
15 August 2023
Quick facts
| Lead sponsor | Optina Diagnostics Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 112 |
| Start date | 8 November 2022 |
| Primary completion | 15 August 2023 |
| Estimated completion | 15 August 2023 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Mydriatic Hyperspectral retinal Camera, (MHRC) and Optical coherence tomography (OCT)
Conditions studied
- Dry Age Related Macular Degeneration — all drugs for Dry Age Related Macular Degeneration →
Sponsor
Optina Diagnostics Inc.
Who can join
50 and older, any sex, with Dry Age Related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This observational, cross-sectional study is designed to explore the feasibility to extract spatial-spectral features from hyperspectral retinal images captured with Optina Diagnostics' MHRC that are characteristic to the different types of drusenoid deposits associated with dry age-related macular degeneration.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06860555
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Optina Diagnostics Inc. trials
Trials by the same sponsor.
- NCT06860568 — The GA in HSI Study · completed
- NCT05903664 — Retinal Deep Phenotyping.TM · withdrawn
- NCT06057493 — RDP Reliability Study · completed
- NCT05903651 — Retinal Deep PhenotypingTM · completed
- NCT05199428 — Optina Eye to Heart Connection · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06860555 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Optina Diagnostics Inc.
- Last refreshed: 6 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06860555.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing